A prospective, multicenter, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus computer assisted vacuum thrombectomy for the treatment of intermediate-high-risk acute pulmonary embolism: Rationale and design of the STORM-PE study.

Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.

Peripheral Neuropathy as an Early Marker in Newborn-Screened Krabbe Disease: The Value of Pre-Confirmatory Neurophysiological Testing.

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis.

Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors.

Considerations in the development of learning health networks for mood disorders.

Defining subgroups of pediatric nephrotic patients with urine proteomics.

Clinical and Angiographic Outcomes of a Novel Thin Strut Poly(L-lactide) Based Bioresorbable Vascular Scaffold in Below the Knee Arterial Disease: The RESOLV I First in Human Study.

Liberation from continuous renal replacement therapy due to renal recovery in adults and children: a literature review and Delphi consensus on clinical practice.

Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era.

Structure From Motion Reconstruction of the Pediatric Larynx: A Clinical Case Series.

Effect of Race, Ethnicity, and Language on Adenotonsillectomy Outcomes in Pediatric Otolaryngology.

Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des rĂŠsultats du traitement antidĂŠpresseur Ă l'aide des scores de risque polygĂŠniques : Rapport sur l'ĂŠtude CAN-BIND-1.

Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial.